Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in VEGF-driven macular edema
NCT01846299Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Sep 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of ranibizumab in macular edema, sponsored by Novartis. Started Oct 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01846299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846299.